Neurocrine Biosciences (NBIX) cleared a benchmark Wednesday.
The Relative Strength Rating for Neurocrine jumped from 77 to 82.
Some technical analysts see a Relative Strength Rating of 80 or higher as a buy signal.
Investors’ Business Daily has a rating that it assigns with a 1 (worst) to 99 (best) score. The rating shows how a stock’s price movement over the last 52 weeks stacks up against all the other stocks in their database. They believe that the best stocks typically have an 80 or higher RS Rating as they launch their biggest climbs.
The company reported -44% EPS growth last quarter. Revenue gains came in at -100%. Even though they are showing negitive numbers, many analysts rate the company as a buy. Of the 13 analysts tracking Neurocrine Biosciences (NBIX), all have recommended some form of “buy.” Five recommended a “strong buy,” while eight recommended a “buy.” On September 4, 2017, NBIX had a mean 12-month target price of $73.33, which represents 28.6% return over the next 12 months.